GT Biopharma

GTBP

Market cap $12.5M

GTBP Hedge Fund Activity: Q1 2026 in Review

42 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2026, worth a combined $657K — up 76% from $374K a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GTBP positions and 10 closed out — a net gain of 5 holders — while 7 added to existing stakes and 5 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $150K. The largest seller was Scientech Research LLC, exiting entirely with an estimated $43K sold.

• 42 institutional investors held GT Biopharma (GTBP) as of Q1 2026, up from 38 in Q4 2025.
• Funds reported $657K of GT Biopharma stock for Q1 2026, up 76% quarter-over-quarter.
• 15 funds opened new GT Biopharma positions in Q1 2026 and 10 closed out, a net change of +5 holders.
• The largest GT Biopharma buyer in Q1 2026 was Geode Capital Management, an estimated $150K added.
• The largest GT Biopharma seller in Q1 2026 was Scientech Research LLC, an estimated $43K sold.

Based on aggregated 13F filings for Q1 2026.